Company Overview
---------
Founded in 2009, Venus Medtech is located in Hangzhou National High-Tech Industrial Development Zone (Binjiang) and is committed to the development and industrialization of transcatheter therapy products for structural heart disease. On December 10th, 2019, the company was listed on the main board of the Hong Kong Stock Exchange (SEHK) with stock code 02500.
The company's all series of “China Intelligently Manufactured " valves has been introduced to more than 60 countries and regions worldwide, including Asia, Europe, South America. Venus Medtech has established comprehensive solutions for structural heart disease, with a complete product pipeline covering all four heart valves, namely TAVR, TPVR, TMVR and TTVR, as well as hypertensive renal denervation (RDN) therapy and relevant accessory products.
+
+Employees
+Patent applications
＞ RMB millioninvested in R&D avg per year
+Real-world implantation cases
yearsThe longest duration of clinical follow-up
+Centers nationwide
.43%Proportion of immediate safe surgery
Data as of end of June,2024
Global landscape
China
Thailand
Malaysia
Singapore
India
Pakistan
Europe
Austria,Belgium,Netherlands,Italy,Spain,Portugal,Denmark,Poland,Switzerland,UK,Greece,Finland,Cyprus,Hungary,Sweden,Norway,Germany,France,Ireland,Turkey,Monaco,Bulgaria,Croatia,Czech Republic,Lithuania,Romania,Slovakia,Slovenia,Estonia,Latvia,Luxemburg,Malta,Iceland,LiechtensteinCanada
Mexico
Brazil
Chile
Argentina
HKSAR
Macao SAR
Uruguay
Colombia
Middle East
Dubai,Saudi Arabia,Jordan,Qatar,Egypt,Morocco,
Bahrain,Kuwait,IsraelKyrgyzstan
Kazakhstan
Venezuela
Australia
